



Prior Authorization
JOHNS HOPKINS HEALTHCARE (MEDICAID) Ventavis - Priority Partners MCO
This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed forms to Johns Hopkins Healthcare at 1-410-424-4607 . Please contact Johns Hopkins Healthcare at 1-888-819-1043 with questions regarding the Prior Authorization process. When conditions are met, we will authorize the coverage of Ventavis - Priority Partners MCO.

Drug Name (select from list of drugs shown) Ventavis (iloprost)
--

Quantity	Frequency	Strength
Route of Administration	Expected Length of Therapy	

Patient Information	
Patient Name:	_____
Patient ID:	_____
Patient Group No.:	_____
Patient DOB:	_____
Patient Phone:	_____

Prescribing Physician	
Physician Name:	_____
Physician Phone:	_____
Physician Fax:	_____
Physician Address:	_____
City, State, Zip:	_____

Diagnosis: _____	ICD Code: _____
-------------------------	------------------------

Comments: _____

Please circle the appropriate answer for each question.	
1. Has the plan authorized this medication in the past for this patient (i.e., previous authorization is on file under this plan)?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: The use of physician samples, or manufacturer product discounts, does not guarantee coverage under the provisions of the medical and/or pharmacy benefit. All pertinent criteria must be met in order to be eligible for benefit coverage. [If yes, skip to question 13.]	
2. Does the patient have a definitive diagnosis of pulmonary arterial hypertension?	<input type="checkbox"/> Y <input type="checkbox"/> N

NOTE: Submission of medical records is required.	
[If no, no further questions.]	
3. Was the diagnosis of pulmonary arterial hypertension confirmed by a cardiologist or pulmonologist by right heart catheterization?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If no, no further questions.]	
4. Does the patient have World Health Organization (WHO) Functional Class III or Class IV symptoms?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If no, no further questions.]	
5. Has the pulmonary arterial hypertension progressed despite surgical treatment and/or maximal medical treatment?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If no, no further questions.]	
6. Has the patient had treatment failure with oral calcium channel blockers?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Patients who have substantial reductions in pulmonary arterial pressure from short acting vasodilators at the time of catheterization may require high doses (e.g., nifedipine 240 milligrams per day (mg/day) or amlodipine 20 mg/day) \ NOTE: Submission of medical records is required.	
[If yes, skip to question 8.]	
7. Is the patient unable to take oral calcium channel blockers, or is their use inappropriate in this patient?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If no, no further questions.]	
8. Does the patient have World Health Organization (WHO) Functional Class IV symptoms?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If yes, skip to question 14.]	
9. Has the patient had a documented trial and inadequate response to generic sildenafil or tadalafil?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If yes, skip to question 11.]	
10. Does the patient have a documented contraindication to generic sildenafil or tadalafil?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If no, no further questions.]	
11. Has the patient had a documented trial and inadequate response to Tyvaso?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If yes, skip to question 14.]	

12. Does the patient have a documented contraindication to Tyvaso?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If yes, skip to question 14.]	
[If no, no further questions.]	
13. Is there clinical documentation showing the patient has experienced improved exercise capacity or a delay in symptom worsening?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If no, no further questions.]	
14. Will the requested drug be used in combination with one or more drugs with the same pharmacology when the patient has not adequately responded to monotherapy?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

Prescriber (Or Authorized) Signature and Date